Annual rank59
Denmark · Healthcare
ALK-Abello
Develops allergy-immunotherapy treatments and management solutions forming the core of its current product portfolio.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Allergy immunotherapy from natural source material to finished medicines
ALK-Abello is a Danish specialist in allergy immunotherapy, medicines made from carefully standardised allergens to change the body's response to a specific trigger over time. Its portfolio includes tablets, injections and drops for respiratory and venom allergies, plus diagnostics, consumer products and emergency adrenaline formats. The group controls an unusual chain from cultivating pollen and other biological materials to clinical development, pharmaceutical production and distribution across 46 markets.
Allergy immunotherapy
The same principle delivered as tablet, injection or drops
ALK uses controlled exposure to a defined allergen to alter the immune response over time. Its formats include clinician-administered injections and sublingual drops or fast-dissolving tablets; marketed tablets cover allergens such as house dust mite, grass, ragweed and Japanese cedar in different countries.
- Allergy-vaccine formats How tablets, injections and drops differ in administration
- How immunotherapy works ALK's scientific explanation of the immune response
- Clinical-trial programme How ALK studies SLIT tablets with hospitals and specialists
- Science and technology Fast-dissolving tablets, biobank data and research partnerships
From farm to pharma
Pollen, mites and venom become standardised medicines
Natural starting materials create a manufacturing challenge: biological variation must not become product variation. ALK grows or collects pollen, mites, venom, food proteins and pet dander, then identifies, extracts, purifies and standardises them before formulation. Its US source-material operation spans farms and facilities in Pennsylvania, California and Washington.
- Production network The farm-to-pharma model and production in Europe and the US
- US source-material farms Cultivation, pollen collection, identity testing and distribution
- ▶ VideoWatch: from farm to pharma ALK's English-subtitled journey from natural material to medicine
- Four production steps Harvesting, extraction, formulation, packaging and distribution
Beyond long-term treatment
Diagnosis, daily management and emergency adrenaline
ALK also makes allergen extracts for diagnostic skin-prick testing and operates in consumer allergy care. For acute anaphylaxis, its portfolio spans an adrenaline auto-injector and the neffy nasal spray in approved markets; a 2026 Canadian approval illustrates the continuing geographic rollout.
- Emergency medicine ALK's adrenaline formats and anaphylaxis focus
- neffy in Canada The 2026 approval of a needle-free adrenaline nasal spray
- Allergy diagnostics Allergen extracts used alongside history and skin-prick tests
- Consumer healthcare Everyday products and digital routes into allergy management
Reach and next research questions
A specialist platform expands into food allergy and data science
ALK reports production in Denmark, France, Spain and the US, offices in more than 20 countries and activity in 46 markets. Its Allergy+ strategy extends respiratory tablets towards food allergy, anaphylaxis and adjacent conditions. Research examples include an investigational peanut SLIT tablet, digital discovery tools and work with McMaster University on IgE memory B cells.
- Company and global footprint Production countries, offices, markets and a century of milestones
- Allergy+ strategy Respiratory tablets, food allergy, anaphylaxis and adjacent areas
- Digital innovation Data platforms, target discovery, apps and wearable-device research
- Peanut-tablet programme The phase II outcome and planned late-2026 phase III start
- The cell that remembers allergy ALK and McMaster's work on a type-2 memory B cell
Official profile sources: Allergy vaccines | ALK · Our company | ALK
Current 2026 update
What has changed in 2026?
UK authorisation announced on 15 June 2026 · 15 June 2026
UK authorisation announced on 15 June 2026latest official update
4company-specific highlights
0%2026 stock return · context only
Revenue
First-quarter revenue rose 18% in local currencies and 16.4% as reported to DKK 1,771 million; International-market tablet sales fell 17% because of shipment phasing.
Profit
Net profit increased 23.4% to DKK 437 million.
2026 outlook raised
ALK raised 2026 guidance to 13–16% revenue growth in local currencies and an EBIT margin of around 26%.
UK paediatric authorisation
UK authorities approved the 1 mg needle-free EURneffy adrenaline spray for children aged four and older weighing 15 to under 30 kilograms.
Official 2026 sources: Three-month interim report (Q1) 2026 (unaudited) · 4 May 2026 · EURneffy® 1 mg approved in UK as the first and only needle-free adrenaline treatment for children · 15 June 2026
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 59 | +39% | +256% | +138% |